Ausgabe 1/2022
Inhalt (25 Artikel)
Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis
Thu H. N. Nguyen, Thanh T. N. Nguyen, Tran T. M. Nguyen, Le H. M. Nguyen, Luan H. Huynh, Hoang N. Phan, Hue T. Nguyen
Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments
Rosa-Maria Ferraiuolo, Bre-Anne Fifield, Caroline Hamm, Lisa A. Porter
USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells
Yang Su, Chenming Wu, Yiming Chang, Lei Li, Yuping Chen, Xuebing Jia, Xinshu Wang, Ying Lv, Bentong Yu, Jian Yuan
STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression
Yuan-Ming Song, Xiao-Long Qian, Xiao-Qing Xia, Ya-Qing Li, Yuan-Yuan Sun, Yu-Mian Jia, Jin Wang, Hui-Qin Xue, Guang-Shen Gao, Xiao-Zi Wang, Xin-Min Zhang, Xiao-Jing Guo
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform
Frederick M. Howard, Gong He, Joseph R. Peterson, J. R. Pfeiffer, Tyler Earnest, Alexander T. Pearson, Hiroyuki Abe, John A. Cole, Rita Nanda
Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer
Weimin Xie, Min Cao, Zhen Zhong, Zongshuai Huang, Xiaqiu Gao, Zicheng Li
Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients
Constantin Sajdik, Eva Schuster, Barbara Holzer, Michael Krainer, Christine Deutschmann, Stefan Peter, Maximilian Marhold, Robert Zeillinger, Eva Obermayr
Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience
Agnese Losurdo, Andrea Vittorio Emanuele Lisa, Mariano Tomatis, Antonio Ponti, Stefania Montemezzi, Elisabetta Bonzano, Lucio Fortunato, Francesca Pellini, Simona Grossi, Marina Bortul, Alfredo Tafà, Giovanni Tazzioli, Matteo Ghilli, Tiziana Mastropietro, Francesco Caruso, Andrea Bonetti, Angelica Della Valle, Alessandra Huscher, Corrado Tinterri, Armando Santoro, Marco Klinger, Mario Taffurelli, Fabio Corsi, Paolo Veronesi, Bettina Ballardini, Laura Biganzoli, Maggiorino Barbero, Romano Polato, Sonia Santicchia
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Fei-Lin Qu, Cai-Jin Lin, Zhe-Bin Liu, A.-Yong Cao, Jiong Wu, Guang-Yu Liu, Ke-Da Yu, Gen-Hong Di, Jun-Jie Li, Zhi-Ming Shao
Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer
Seong Soon Kwon, Bo Da Nam, Min-Young Lee, Min Hyuk Lee, Jihyoun Lee, Byoung-Won Park, Duk Won Bang, Soon Hyo Kwon
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy
Song Yi Park, Koung Jin Suh, Dae-Won Lee, Han Suk Ryu, Miso Kim, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Jee Hyun Kim, In Ae Park, Seock-Ah Im
Axilla lymph node dissection can be safely omitted in patients with 1–2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis
Weiqi Gao, Shuangshuang Lu, Yufei Zeng, Xiaosong Chen, Kunwei Shen
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers
Maryam Nemati Shafaee, Kristina Goutsouliak, Heather Lin, Therese B. Bevers, Angelica Gutierrez-Barrera, Melissa Bondy, Banu Arun
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer
Danielle M. File, Tomas Pascual, Allison M. Deal, Amy Wheless, Charles M. Perou, E. Claire Dees, Lisa A. Carey
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
Kristen D. Whitaker, Xiaoliang Wang, Mustafa Ascha, Timothy N. Showalter, Heather G. Lewin, Gregory S. Calip, Lori J. Goldstein
Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer
Tanya Gupta, Natasha Purington, Mina Liu, Summer Han, George Sledge, Lidia Schapira, Allison W. Kurian
Postmenopausal overweight and breast cancer risk; results from the KARMA cohort
Marie Klintman, Ann H. Rosendahl, Benjamin Randeris, Mikael Eriksson, Kamila Czene, Per Hall, Signe Borgquist
Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study
Christina M. S. Hassing, Mathias Kvist Mejdahl, Anne-Vibeke Lænkholm, Niels Kroman, Ann Søegaard Knoop, Tove Holst Filtenborg Tvedskov
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
Julia Levy, Fady Farag, John Cole
Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions
Claire E. P. Smith, Paul K. Marcom, Zahi Mitri, Naomi Y. Ko
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
Mariya Rozenblit, Kim Blenman, Malini Harigopal, Emily Reisenbichler, Kamaljeet Singh, Tao Qing, Eiman Ibrahim, Shakti Ramkissoon, Sem Asmelash, Hao-Kuen Lin, Mustimbo Roberts, Jeffrey Ross, Richard S. P. Huang, Lajos Pusztai
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study
Grace M. Choong, Savannah Liddell, Roberto A. Leon Ferre, Ciara C. O’Sullivan, Kathryn J. Ruddy, Tufia C. Haddad, Timothy J. Hobday, Prema P. Peethambaram, Minetta C. Liu, Matthew P. Goetz, Karthik V. Giridhar
Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: correspondence
Rujittika Mungmunpuntipanjtip, Won Sriwijitalai, Viroj Wiwanitkit
Strict definition of a small tumor in breast cancer should be revisited
Ahmet Necati Sanli, Kadri Altundag
De-escalation of breast cancer treatment for Her2-positive breast cancer
Parinita Swarnkar, Lara Mokbel, Kefah Mokbel